ArticleFrontiers in medicine2026
The correlation between the systemic inflammation response index and 6-month readmission risk in patients with hypertensive heart disease-related heart failure and its predictive model.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between the Systemic Inflammation Response Index (SIRI) and the risk of 6-month readmission in patients with hypertensive heart disease-related heart failure (HHD-HF), and develop and validate a nomogram prediction model integrating SIRI. Methods: A retrospective cohort of 158 hypertensive heart disease-related heart failure (HHD-HF) patients (June 2022-December 2024) was enrolled. Baseline clinical data, laboratory indicators, and cardiac structural and functional parameters were collected. Patients were split 7:3 into training ( Results: The LVMI (OR = 1.02, Conclusion: This nomogram incorporating LVMI, diabetes history, and SIRI effectively predicts 6-month readmission in HHD-HF patients, with discriminative ability and good calibration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.